Bruker Corporation

Bruker Corporation

439.63
USD
-7.03
(-1.57%)
Feb 16Next Earn
Bruker Corporation
NASDAQ:BRKRP
(Nasdaq Stock Market)

Recent

price

439.63

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
1,305
1,652
1,791
1,839
1,809
1,624
1,611
1,766
1,896
2,073
1,988
2,418
2,531
2,965
3,366
3,437
3,513
Sales/Revenue/Turnover
12.38
9.95
10.19
9.28
7.46
9.86
12.88
13.53
14.63
14.73
13.45
17.64
18.27
16.5
11.26
6.87
9.73
Operating Margin (%)
36
53
59
61
60
53
54
64
65
76
81
89
89
115
184
220
229
Depreciation Expense
95
92
78
80
57
102
154
79
180
197
158
277
297
427
113
-9
-123
Net Income, GAAP
35.51
35.4
43.46
34.35
41.16
18.05
13.01
59.4
26.03
29.39
28.52
28.71
28.12
21.63
44.18
133.18
- -
Effective Tax Rate (%)
7.31
5.59
4.33
4.35
3.13
6.26
9.53
4.45
9.48
9.51
7.94
11.46
11.72
14.41
3.36
-0.25
-3.51
Profit Margin (%)
220
438
628
783
784
677
751
834
705
1,151
1,133
1,533
1,199
962
772
933
985
Working Capital
87
219
336
354
354
265
392
416
323
860
889
1,264
1,235
1,235
2,181
1,991
1,703
LT Debt
527
625
710
850
772
733
693
734
928
938
974
1,085
1,132
1,413
1,815
2,510
2,343
Total Equity
13.72
10.67
8.42
8.3
5.16
10.81
14.64
7.72
15.44
13.24
9.13
12.91
12.28
12.57
3.96
-0.51
- -
Return on Invested Capital (%)
14.1
10.85
8.6
7.74
5.29
10.25
15.61
7.38
15.53
13.45
8.88
13
12.55
16.89
4.06
-0.67
- -
Return on Capital (%)
20.26
16.11
11.67
10.32
7.03
13.62
21.75
11.13
22.16
21.87
16.9
27.28
27.16
34.3
7.16
-1.06
-7.09
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
8
10
10
LT Borrowings
1,663
1,815
1,703
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
- -
- -
- -

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,104
2,225
2,157
Cash, Cash Equivalents & STI
133
223
167
Accounts Receivable, Net
543
546
564
Inventories
1,122
1,120
1,103
Total Current Liabilities
1,355
1,205
1,172
Payables & Accruals
269
200
208
ST Debt
8
10
10
Deferred Revenue
480
445
429

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.91%
21.45%
38.29%
Free Cash Flow
-2.97%
-21.82%
-89.78%
Net Income, GAAP
6.63%
-10.89%
-107.6%
Sales/Revenue/Turnover
8.05%
11.82%
2.08%
Total Cash Common Dividend
- -
-2.84%
-37.09%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
722
801
864
980
3,366
2025
801
797
861
977
3,437
2026
823
839
874
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Bruker Corporation (Nasdaq: BRKR) develops, manufactures, and distributes high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at molecular, cellular, and microscopic levels. The company offers a broad portfolio of products including nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) spectrometers; mass spectrometry systems; X-ray diffraction, scattering, and microscope analyzers; infrared, near-infrared, and Raman spectroscopy instruments; fluorescence and electron microscopy solutions; preclinical imaging systems; elemental analyzers; surface plasmon resonance systems; microbiology and clinical diagnostic tools such as ClinMASS and ClinDART kits; CBRNE detectors; semiconductor metrology equipment; and laboratory automation, data management, and test & measurement solutions. These products support applications in life science molecular research, pharmaceuticals, biotechnology, materials science, microscopy and nanoanalysis, industrial quality control, preclinical imaging, clinical phenomics and proteomics, and clinical microbiology. Founded in 1960 and headquartered in Billerica, Massachusetts, Bruker operates globally with over 11,000 employees across more than 90 locations on all continents, serving academic, governmental, pharmaceutical, biotechnology, and industrial customers. In April 2025, Bruker announced a majority investment in RECIPE Chemicals + Instruments GmbH, a Munich-based provider of clinical diagnostic assays, enhancing its small molecule diagnostics capabilities through integration of RECIPE's ClinMASS kits for EVOQ liquid chromatography triple-quadrupole mass spectrometers and upcoming high-throughput ClinDART kits for chromatography-free workflows on EVOQ-DART systems. Earlier, in 2024, the company acquired Dynamic Biosensors GmbH to strengthen its biosensor portfolio for molecular interaction analysis, complementing high-performance surface plasmon resonance systems like SPR #64 'Triceratops' for pharmaceutical and biotechnology drug discovery. Bruker also secured approximately $10 million in federally funded NMR system orders in October 2025 from institutions including the New York Structural Biology Center, University of Delaware, and Northwestern University, while initiating a major cost savings program targeting $100-120 million in annual reductions by fiscal 2026 amid market pressures.

Company News

  • Bruker Announces that Institute Director, Biopharma Entrepreneur and Immunology Leader Dr. Eicke Latz will join its Board of Directors

  • Should You Continue to Retain Bruker Stock in Your Portfolio?

  • Bruker: Five Quarters Of Orders Are Still Waiting To Show Up In Revenue

  • Bruker Corporation (BRKR) Q3 2026 Earnings Call Transcript

  • Bruker Q3 Earnings Call Highlights

  • Here's What Key Metrics Tell Us About Bruker (BRKR) Q3 Earnings

  • Bruker (BRKR) Q3 Earnings and Revenues Surpass Estimates

  • Bruker Reports Third Quarter 2026 Financial Results

  • Bruker Announces Date and Time of Third Quarter 2026 Earnings Release and Webcast

  • Is Bruker Corp (BRKR) a Bargain After 3.1% Drop? GF Value Says Undervalued

  • Bruker Gains 66.3% in a Year: What's Driving the Rally?

  • Bruker Corp (BRKR) Shares Fall 5.3% -- GF Value Says Still Overvalued

  • Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution

  • Why Bruker (BRKR) is a Top Momentum Stock for the Long-Term

  • Bruker (NASDAQ:BRKR) Sets New 1-Year High – Should You Buy?

  • Neuralink Stock: How to Invest Before the IPO

  • Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research

  • Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research

  • Bruker Sees AI-Fueled Semiconductor Demand, Targets Critical Q4 Revenue Rebound

  • Bruker Corporation (BRKR) Presents at Bank of America Global Healthcare Conference 2026 Transcript